Early Antiretroviral Therapy for Patients With Acute AIDS-Related Opportunistic Infections: A Cost-Effectiveness Analysis of ACTG A5164

REFERENCES

• Schwarcz S, Hsu L, Dilley JW, Loeb L, Nelson K, Boyd S. Late diagnosis of HIV infection: trends, prevalence, and characteristics of persons whose HIV diagnosis occurred within 12 months of developing AIDS. J Acquir Immune Defic Syndr 2006;43(4):491–494.
   PubMed Web of Science ®Google Scholar
• Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One. 2009;4(2):e4445.
   PubMed Web of Science ®Google Scholar
• Late HIV testing - 34 states, 1996-2005. MMWR Morb Mortal Wkly Rep. 2009;58(24):661–665.
   PubMedGoogle Scholar
• Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter random-ized strategy trial. PLoS ONE. 2009;4(5):e5575.
   PubMed Web of Science ®Google Scholar
• Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001344(11):824–831.
   Web of Science ®Google Scholar
• Weinstein MC, Goldie SJ, Losina E, et al. Use of geno-typic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001; 134(6):440–450.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-in-fected adults and adolescents. December 1,2009. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed March 2, 2010.
   Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Siegel JE, Weinstein MC, Russell LB, Gold MR. Recom-mendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16)1 339–1341.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Scott CA, Walensky RP, Losina E, Freed-berg KA, Sax PE. The cost-effectiveness of HLA-B"5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025–2033.
   PubMed Web of Science ®Google Scholar
• Chan PS, Khalid A, Longmore LS, Berg RA, Kosiborod M, Spertus JA. Hospital-wide code rates and mortality before and after implementation of a rapid response team. JAMA. 2008;300(21):2506–2513.
   PubMed Web of Science ®Google Scholar
• Dacey MJ, Mirza ER, Wilcox V, et al. The effect of a rapid response team on major clinical outcome measures in a community hospital. Crit Care Med. 2007; 35(9):2076–2082.
   PubMed Web of Science ®Google Scholar
• Multicenter AIDS Cohort Study (MACS) Public Dataset: Release PO4. Springfield, VA: National Technical Informa-tion Service; 1995.
   Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954.
   PubMed Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Medi-care Physician Fee Schedule. 2008. http://www.cms.hhs.gov/PhysicianFeeSched/PFSRVF/list.asp#Top0fPage. Accessed November 2,2009.
   Google Scholar
• Centers for Medicare and Medicaid Services. Clinical Laboratory Fee Schedule. 2008. http://www.cms.hhs.gov/ClinicalLabFeesched/02_clinlab.asp. Accessed November 2,2009.
   Google Scholar
• US Bureau of Labor Statistics. Consumer Price Index (CPI). 2008. http://www.b1s.gov/cpi/. Accessed October 21, 2009.
   Google Scholar
• American Medical Association. CPT Code/Relative Value Search. 2009. https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?_requestid=570127. Accessed February 24,2010.
   Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006;20(5):711–718.
   PubMed Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazana-vir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685–694.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–354.
   PubMed Web of Science ®Google Scholar
• Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infec-tion. N Engl J Med. 2008;359(4):355–365.
   PubMed Web of Science ®Google Scholar
• Yazdanpanah Y, Fagard C, Descamps D, et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441–1449.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and effi-cacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resis-tant virus: a phase 11 randomised controlled trial. Lancet. 2007;369(9569)1261–1269.
   Web of Science ®Google Scholar
• Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lan-cet. 2007;370(9581):29–38.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a ran-domised, double-blind, placebo-controlled trial. Lancet. 2007;370(9581):39–48.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14)1 429–1441.
   Web of Science ®Google Scholar
• Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experi-enced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40(4):404–412.
   PubMed Web of Science ®Google Scholar
• Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 21D/3 study in the US and Canada. Presented at: 14th Conference on Retro-viruses and Opportunistic Infections; 2007; Los Angeles, CA. Abstract 104bLB.
   Google Scholar
• Reynes J, Arasteh K, Clotet B, et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS. 2007;21(8): 533–543.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–997.
   PubMed Web of Science ®Google Scholar
• University HealthSystem Consortium. CDP online report. https://www.uhc.edu. Accessed November 2,2009.
   Google Scholar
• Bozzette SA, Joyce G, McCaffrey DF, et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001344(11):817–823.
   Google Scholar
• US Bureau of Labor Statistics. Occupational Employment Statistics (OES). 2008. http://data.b1s.gov/oes/search.jsp. Accessed June 18, 2009.
   Google Scholar
• Johnson D, Friedman R, Ziember D, Lennox JL, Del Rio C. Patients with newly diagnosed HIV who are discharged from a large urban hospital in the United States rarely begin antiretroviral therapy and few achieve an undetectable viral load. Presented at: XVII International AIDS Conference; August 3–8, 2008; Mexico City, Mexico. WEPE0223.
   Google Scholar
• Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflamma-tory syndrome in HIV patients in South Africa: a prospec-tive study. AIDS. 2008;22(5):601–610.
   PubMed Web of Science ®Google Scholar
• Sax PE, Islam R, Walensky RP, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41(9)1 316–1323.
   Web of Science ®Google Scholar
• Sorensen SV, Frick KD, Wade A, Simko R, Burge R. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia. Clin Ther. 2009;31(4):862–879.
   PubMed Web of Science ®Google Scholar
• Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effective-ness standard. Value Health. 2009;12(1):80–87.
   PubMed Web of Science ®Google Scholar
• HIV Epidemiology Unit, Georgia Division of Public Health, Georgia Department of Community Health. Georgia HIV/ AIDS Surveillance Summary: data through December 31, 2007. 2007. http://health.state.ga.us/epi/hivaids/. Accessed July 8, 2010.
   Google Scholar
• Torok M, Yen N, Chau T, et al. Randomised controlled trial of immediate versus deferred antiretroviral therapy in HIV-associated tuberculous meningitis. Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco, CA. Abstract H–1224.
   Google Scholar
• Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS. 2005;19(4):399–406.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitu-tion inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS. 2005;19(10):1043–1049.
   PubMed Web of Science ®Google Scholar
• Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus delayed initiation of antiretroviral therapy for con-current HIV infection and cryptococcal meningitis in sub-Saharan Africa. Clin Infect Dis. 2010;50(11):1532–1538.
   PubMed Web of Science ®Google Scholar
• Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr. 2009;51(2):130–134.
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Filler SG, Chetchotisakd P, et al. Cryp-tococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococ-cal meningitis: a prospective multicenter study. Clin Infect Dis. 2009;49(6):931–934.
   PubMed Web of Science ®Google Scholar
• Park WB, Choe PG, Jo JH, et al. Immune recon-stitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS. 2006;20(18):2390–2392.
   PubMed Web of Science ®Google Scholar
• Croda J, Croda MG, Neves A, De Sousa dos Santos S. Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit. Crit Care Med. 2009;37(5)1 605–1611.
   Web of Science ®Google Scholar
• Red Book. Montvale, NJ: Thomson PDR.
   Google Scholar